Nano Publications Nano Publications

01.

Publications

Nanobiotix has been a pioneer in the field of nanomedicine for more than a decade. The idea is to follow a different path than other Pharma or Biotech companies by treating patients with nanophysical methods at the heart of the cell.

Over the years numerous publications and abstracts have been published which most of them are combined in this online bibliography of Nanobiotix.

01. NBTXR3 Clinical Data

Publications in this section cover results of clinical trials with NBTXR3. The reports are published in peer-reviewed journals.

Peer-review means that the report has been reviewed by one or more experts with competence in the relevant field before it was accepted for publication by the journal.

02. NBTXR3 Pre-clinical Data (In Vitro and In Vivo Studies)

Publications in this section cover in vitro and in vivo data of NBTXR3. In vitro means that NBTXR3 was studied in cells outside their normal biological context.

In vivo refers to tests of NBTXR3 in animals. The reports are published in peer-reviewed journals (see explanation in clinical trials publications).

03. Miscellaneous

In this section publications of Nanobiotix can be found which are related to Nanobiotix’ other technologies or specific research projects.

2020 – Review of Clinical Application of Radiation Enhancing Nanoparticles

2019 – Bulletin Cancer – NBTXR3 improves pathological response

2017 – Nano-sized cytochrome p450 3a4 inhibitors to block hepatic – Paolini et al.

2017 – A new opportunity for nanomedicines – Paolini et al.

2015 – Metals as radio-enhancers in oncology – Pottier et al.

2015 – The future of nanosized radiation enhancers – Pottier et al.

2010 – Concept of NBTXR3 – Borghi et al.

2010 – Nanocarrier for Photodynamic Therapy – Thienot et al.

2010 – Silica Nanoparticles – Simon et al.

2010 – Combinations of proteins with Nano-Systems – Di Marco et al.

02.

Congress Abstracts

Congresses are a key element for Nanobiotix to publish scientific data and results. This section lists abstracts that have been published by Nanobiotix over the last decade.

Laurent Levy at S3 Odéon

01. NBTXR3 Clinical Data

Abstracts in this section cover results of clinical trials with NBTXR3.

  • All
  • Head  &  Neck
  • Liver
  • Lung
  • Pancreas
  • Rectum
  • STS

2021 – A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients

2021 – Study of Novel Radioenhancer NBTXR3 Plus Radiotherapy in Patients With Locally Advanced Soft Tissue Sarcoma: Results of the Long-Term Evaluation in the Phase II/III Act.In.Sarc Trial

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

2021 – Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2021 – NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial

2021 – Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients

2021 – NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in patients with advanced cancers: phase I trial

2021 – Long-term results from the phase II/III Act.In.Sarc trial evaluating NBTXR3 in locally advanced STS

2021 – NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2021 – Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial

2021 – Radiation enhancing NBTXR3 for the treatment of cisplatin-ineligible locally advanced HNSCC patients

2021 – Results from the phase I dose-escalation study of the radiation enhancer NBTXR3 for the treatment of HCC and liver metastases

2021 – A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial

2020 – Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers

2020 – NANORAY-103: Phase I/II trial of NBTXR3 activated by SBRT in patients with HCC and liver metastases

2020 – RT-activated hafnium oxide nanoparticles in cisplatin-ineligible locally advanced HNSCC patients

2020 – NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Combination With Anti-PD-1 Therapy: A Phase I Study

2020 – Phase I/II Study Of Radiation Enhancing Hafnium Oxide Nanoparticles NBTXR3 Activated by SBRT in HCC and Liver Metastases Patients

2020 – NBTXR3 radiation enhancing hafnium oxide nanoparticles: RP2D for the treatment of HCC and liver metastases

2020 – Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy

2020 – Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients

2020 – Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study

2020 – Treatment of hepatocellular carcinoma and liver metastases with hafnium oxide nanoparticles activated by SBRT: a phase I/II trial

2020 – ESTRO – NBTXR3 for the Treatment of Advanced Liver Cancers

2020 – SITC – NBTXR3 with Anti-PD-1 Therapy

2020 – SITC – NBTXR3 From Bench to Bedside

2020 – ESTRO – NBTXR3 for the Treatment of Locally Advanced HNSCC

2020 – ASTRO – NBTXR3 in HNSCC

2020 – ASTRO – NBTXR3 in Advanced Liver Cancers

2020 – ASTRO – NBTXR3 in Combination with Anti-PD-1

2020 – ESMO – NBTXR3 in HCC and Liver Metastases

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

2020 – MHNCS – NBTXR3 for locally advanced HNSCC

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

2020 – ASCO GI – Treatment of liver cancers with NBTXR3

2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy

2019 – NBTXR3 for the treatment of locally advanced HNSCC in frail and/or elderly patients: a phase I/II study

2019 – Phase I study of hafnium oxide nanoparticles activated by Intensity Modulated Radiation Therapy (IMRT) as a new therapeutic option for elderly or frail HNSCC patients

2019 – Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis

2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial

2019 – ESMO IO – NBTXR3 with anti-PD-1

2019 – RSNA – Treatment of locally advanced HNSCC by NBTXR3

2019 – SIOG – NBTXR3 for the treatment of elderly/frail HNSCC patients

2019 CTOS NBTXR3 in STS phase II/III trial

2019 – ESMO – NBTXR3 activated by SBRT in liver cancers

2019 – ASTRO – NBTXR3 for the treatment liver cancers

2019 – ASTRO – NBTXR3 for the treatment of solid tumors

2019 – ESMO WGI – NBTXR3 in unresectable liver cancers

2019 – ASCO – NBTXR3 in Liver Cancers

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

2019 – AHNS – Phase I/II NBTXR3 in combination with anti-PD-1

2019 – ESTRO – Randomized NBTXR3 trial in STS

2019 – ESTRO – NBTXR3 activated by SBRT in liver cancers

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis

2018 – ASTRO – NBTXR3 Anti-Tumor Immune Response

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

2018 – SIOG – NBTXR3 In Elderly With HNSCC

2018 – ASTRO – NBTXR3 Exploratory Dosimetric Study

2018 – ASTRO – NBTXR3 in solid tumors

2018 – ESMO – Phase II/III NBTXR3 in STS

2018 – ASTRO 2018 – NBTXR3 in elderly HNSCC

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

2018-ASTRO 2018- NBTXR3 in liver cancers

2018 – ESMO – NBTXR3 in HCC and Liver Metastasis

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

2017 – Abstract SITC Conference Maryland – Clinical

2017 – A phase 1 trial of NBTXR3 nanoparticles activated by IMRT in the treatment of advanced-stage head and neck carcinoma

2017 – Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients

2014 – ASCO Abstract – Preliminary Data NBTXR3 Soft Tissue Sarcoma – Bonvalot et al.

02. NBTXR3 Pre-clinical Data (In Vitro and In Vivo Studies)

Abstracts in this section cover  in vitro and in vivo data of NBTXR3.

In vitro means that NBTXR3 was studied in cells outside their normal biological context. In vivo refers to tests of NBTXR3 in animals.

  • All
  • In Vitro
  • In Vivo

2021 – Radiotherapy-activated NBTXR3 nanoparticles Increase CD8+ T cell infiltration and diversity in tumors, and modulate the immunopeptidome of cancer cells

2021 – Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice

2021 – Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside

2020 – NBTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant murine lung cancer model

2020 – SITC – NBTXR3 Generates Long Term Immune Memory

2020 – SITC – TCR Repertoire

2020 – SITC – NBTXR3 From Bench to Bedside

2019 – NBTXR3 Activated By Radiotherapy Generates an Anti-Tumor Immune Response

2019 – RSNA – Anti-tumor immune response induced by NBTXR3

2019 – ASTRO – NBTXR3 generates an anti tumor immune response

2019 – ASCO – NBTXR3 induces antitumor immune response

2018 – ASCO – NBTXR3 generates an anti-tumor immune response

2018 – OncoRad – NBXTR3 Abscopal Effect

2018 – AACR – Activation of the cGAS-STING pathway by NBTXR3

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

2017 – Abstract SITC Conference Maryland – Non Clinical

2017 – Abstract AACR-EORTC-NCI

2017 – Immunotherapy Workshop

2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro

2017 – AACR Abstract – NBTXR3 anti-tumor efficacy in vivo

2016 – SITC Abstract – NBTXR3 for in situ cancer vaccination

2011 – ECCO Abstract – NBTXR3 as promising cancer therapy – Magiorella et al.

2011 – AACR Abstract – NBTXR3 radioenhancement and anti-tumor effect in vitro – Magiorella et al.

2010 – ESTRO Abstract – hafnium Oxide nanoparticles as anti cancer agent – Deutsch et al.

03. Miscellaneous

In this section abstracts of Nanobiotix can be found which are related to Nanobiotix other technologies or specific research projects.

2017 – AACR-EORTC-NCI Monte Carlo Calculation

2015 – Clinical Sciences and Drug Discovery Abstract – Use of metals as nano-sized radiation enhancers – Pottier et al.

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

2010 – GDR Photomed Abstract – Silica Nanoparticles for Photodynamic Therapy – Thienot et al.

2010 – CLINAM Abstract – Expected and Unexpected Side Effects of Nanodrugs – Levy et al.

NEED MORE HELP?

Don’t hesitate to contact our team. We are looking forward to guide you.

Contact Us
25
PUBLICATIONS
112
ABSTRACTS
143
DIAGRAMS
233
AUTHORS

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer